A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies

BACKGROUND: Polo-like kinase 1 (Plk1) has an important role in mitosis. Volasertib (BI 6727), a potent and selective cell cycle kinase inhibitor, induces mitotic arrest and apoptosis by targeting Plk; this phase I study sought to determine its maximum tolerated dose (MTD) in Asian patients with adva...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, C-C, Su, W-C, Yen, C-J, Hsu, C-H, Su, W-P, Yeh, K-H, Lu, Y-S, Cheng, A-L, Huang, D C-L, Fritsch, H, Voss, F, Taube, T, Yang, J C-H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021529/
https://www.ncbi.nlm.nih.gov/pubmed/24755882
http://dx.doi.org/10.1038/bjc.2014.195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021529/
https://www.ncbi.nlm.nih.gov/pubmed/24755882
http://dx.doi.org/10.1038/bjc.2014.195

Ejemplares similares